FibroBiologics, Inc. (NASDAQ:FBLG) Financings

FibroBiologics, Inc.

Financings

RaiseDate
Private placement of shares of common stock and accompanying warrants
Closed: US$500,000 raised · US$1.675 a share · Warrants at US$1.55 for 60 months
Buyers: Hamid Khoja, Ph.D. (298,508 shares of common stock and accompanying warrants to purchase up to 298,508 shares)
Insiders: The entire placement was purchased by Chief Scientific Officer Hamid Khoja, Ph.D.
Use of proceeds: General corporate purposes and working capital
Sep 17, 2026
Private placement of shares of common stock (or pre-funded warrants) with series A and short-term series B warrants
Closed: US$3M raised · US$0.735 a share · Warrants at US$0.735 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital and general corporate purposes
Jun 29, 2026
Registered direct offering of registered direct offering
Closed: US$2.5M raised
Apr 30, 2026
Registered direct offering of common stock, with concurrent private placement of unregistered warrants
Closed: US$1.7M raised · US$0.33 a share · Warrants at US$0.33 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital and general corporate purposes
Dec 16, 2025
Registered direct offering of common stock, with concurrent private placement of unregistered warrants
Closed: US$1.5M raised · US$0.335 a share · Warrants at US$0.335 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital and general corporate purposes
Nov 25, 2025
Registered direct offering of common stock and pre-funded warrants, with concurrent private placement of unregistered warrants
Closed: US$4M raised · US$0.3303 a share · Warrants at US$0.3303 for 60 months
Buyers: existing shareholder (3,540,000 shares of common stock and pre-funded warrants to purchase 8,570,203 shares, paid with gold coins)
Use of proceeds: General corporate purposes, including the satisfaction of debt
Nov 20, 2025
Convertible promissory notes (advances under SEPA)
Tranche closed: US$5M in the latest tranche · D. Boral Capital LLC
Dealers: D. Boral Capital LLC (lead)
Buyers: YA II PN LTD. (Yorkville) (Up to $25 million of common stock over two years; first $15 million advanced via convertible promissory notes, $5 million funded); YA II PN, LTD. (Yorkville) (third $5 million tranche of convertible promissory notes under the SEPA)
Use of proceeds: General corporate purposes, including R&D programs and the upcoming Phase 1/2 diabetic foot ulcer clinical trial
Jun 16, 2025

Read by 6ix AI from the company's releases